From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Current Medical Research and Opinion

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1185/03007990802710422 PMID 19232040
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• "Sick fat," metabolic disease, and atherosclerosis.

  2009cited by this paper
• Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.

  2008cited by this paper
• Effects of intensive glucose lowering in type 2 diabetes.

  2008cited by this paper
• Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real‐Life Effectiveness and Care Patterns of Diabetes Management (RECAP‐DM) Study

  2008cited by this paper
• Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

  2008cited by this paper
• 10-year follow-up of intensive glucose control in type 2 diabetes.

  2008cited by this paper
• Images in clinical medicine. Paget's disease of the mandible.

  2008cited by this paper
• Comorbid Conditions and Glycemic Control in Elderly Patients with Type 2 Diabetes Mellitus, 1988 to 1994 to 1999 to 2004

  2008cited by this paper
• Active sugar transport in health and disease

  2007cited by this paper
• Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells.

  2007cited by this paper
• Bodyweight Changes Associated with Antihyperglycaemic Agents in Type 2 Diabetes Mellitus

  2007cited by this paper
• Sodium-glucose cotransporter inhibitors for diabetes.

  2007cited by this paper
• Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: A series of retrospective analyses of data from 1998 through 2002.

  2006cited by this paper
• Islet beta cell failure in type 2 diabetes.

  2006cited by this paper
• Diagnosis of insulin resistance and associated syndromes: the spectrum from the metabolic syndrome to type 2 diabetes mellitus

  2005cited by this paper
• Type 2 diabetes, insulin secretion and beta-cell mass.

  2005cited by this paper
• Phlorizin: a review

  2005cited by this paper
• Insulin resistance, the insulin resistance syndrome, and cardiovascular disease.

  2005cited by this paper
• Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes.

  2005cited by this paper
• SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose.

  2005cited by this paper
• Long-term outcome of renal glucosuria type 0: the original patient and his natural history.

  2004cited by this paper
• Clinical inertia in the management of Type 2 diabetes metabolic risk factors

  2004cited by this paper
• The sodium/glucose cotransport family SLC5

  2003cited by this paper
• Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association

  2003cited by this paper
• Molecular analysis of the SGLT2 gene in patients with renal glucosuria.

  2003cited by this paper
• Glucotoxicity and beta-cell failure in type 2 diabetes mellitus.

  2003cited by this paper
• Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins

  2003cited by this paper
• Role of human liver, kidney, and skeletal muscle in postprandial glucose homeostasis.

  2002cited by this paper
• Hyperglycemia and Insulin Resistance: Possible Mechanisms

  2002cited by this paper
• Renal gluconeogenesis: its importance in human glucose homeostasis.

  2001cited by this paper
• Renal Na(+)-glucose cotransporters.

  2001cited by this paper
• Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

  2000cited by this paper
• Glucose transporters: Structure, function and consequences of deficiency

  2000cited by this paper
• T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes.

  1999cited by this paper
• I. Glucose galactose malabsorption.

  1998cited by this paper
• Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Effects of phlorizin and acipimox on insulin resistance in STZ-diabetic rats.

  1995cited by this paper
• Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

  1995cited by this paper
• Hyperglycemie and Microvascular and Macrovascular Disease in Diabetes

  1995cited by this paper
• Molecular physiology of sodium-glucose cotransporters.

  1994cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression.

  1991cited by this paper
• Insulin resistance in rats with non-insulin-dependent diabetes induced by neonatal (5 days) streptozotocin: evidence for reversal following phlorizin treatment.

  1990cited by this paper
• Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats.

  1987cited by this paper
• Phloretin - an uncoupler and an inhibitor of mitochondrial oxidative phosphorylation.

  1983cited by this paper
• Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects.

  1971cited by this paper
• Metabolic and glucosuria studies on naringin and phloridzin.

  1958cited by this paper

• Sex differences in trial representation and the cardiovascular effectiveness of newer glucose‐lowering agents in patients with and without type 2 diabetes: A systematic review and meta‐analysis of cardiovascular outcome trials

  2026cites this paper
• Dapagliflozin exerts anti-apoptotic effects by mitigating macrophage polarization via modulation of the phosphoinositide 3-kinase/protein kinase B signaling pathway

  2025cites this paper
• Cardiovascular effectiveness of newer glucose-lowering agents, with and without baseline lipid-lowering therapy in type 2 diabetes: A systematic meta-analysis of cardiovascular outcome trials and real-world evidence.

  2024cites this paper
• Obesity, diabetes mellitus, and cardiometabolic risk: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023

  2023cites this paper
• 3-tert-Butyl-4-hydroxyanisole perturbs renal lipid metabolism in vitro by targeting androgen receptor-regulated de novo lipogenesis.

  2023cites this paper
• Administration of sodium-glucose cotransporter-2 inhibitors in kidney transplant patients with diabetes: a systematic review and meta-analysis

  2023cites this paper
• Effect of sodium‐glucose cotransporter 2 inhibitors on the rate of decline in kidney function: A systematic review and meta‐analysis

  2023cites this paper
• Why does type 2 diabetes mellitus impair weight reduction in patients with obesity? A review

  2023cites this paper
• DEVELOPMENT AND VALIDATION OF HPTLC BIOANALYTICAL METHOD FOR SIMULTANEOUS ESTIMATION OF DRUGS PRESCRIBED IN THE COMORBID CONDITION OF DIABETES AND CARDIOVASCULAR DISEASE

  2022cites this paper
• Concomitant medications, functional foods, and supplements: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022

  2022cites this paper
• A Deep Insight Into Regulatory T Cell Metabolism in Renal Disease: Facts and Perspectives

  2022cites this paper
• Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022

  2022cites this paper
• Sodium–glucose cotransporter 2 inhibitor-induced euglycemic diabetic ketoacidosis in a patient with coronavirus disease 2019: a case report

  2022cites this paper
• Ten things to know about ten cardiovascular disease risk factors – 2022

  2022cites this paper
• Ten things to know about ten cardiovascular disease risk factors

  2021cites this paper
• Sodium-Glucose Co-transporter-2 Inhibitors and Nephroprotection in Diabetic Patients: More Than a Challenge

  2021cites this paper
• 2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes

  2021cites this paper
• Benefits and harms of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2‐I) and renin–angiotensin–aldosterone system inhibitors (RAAS‐I) versus SGLT2‐Is alone in patients with type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials

  2021cites this paper
• Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity

  2020cites this paper
• 2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases.

  2020cites this paper
• Euglycemic diabetic ketoacidosis caused by canagliflozin: a case report

  2020cites this paper
• Second Revolution in Cardiovascular Prevention.

  2020cites this paper
• Early administration of empagliflozin preserved heart function in cardiorenal syndrome in rat.

  2019cites this paper
• Effects of newly introduced antidiabetic drugs on autophagy.

  2019cites this paper
• Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy

  2019cites this paper
• SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis.

  2018cites this paper
• Fluorine-Directed Glycosylation Enables the Stereocontrolled Synthesis of Selective SGLT2 Inhibitors for Type II Diabetes.

  2018cites this paper
• Dapagliflozin/Saxagliptin Fixed-Dose Tablets: A New Sodium-Glucose Cotransporter 2 and Dipeptidyl Peptidase 4 Combination for the Treatment of Type 2 Diabetes

  2018cites this paper
• Il trattamento del diabete mellito di tipo 2 nei pazienti affetti da malattia renale cronica: cosa aspettarsi dai nuovi ipoglicemizzanti orali

  2017cites this paper
• Characteristics and Impact Factors of Renal Threshold for Glucose Excretion in Patients with Type 2 Diabetes Mellitus

  2017cites this paper
• Neue Therapieansätze bei Typ-2-Diabetes und hohem kardiovaskulärem Risiko

  2017influential citation
• Sodium‐glucose co‐transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician

  2017cites this paper
• Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels.

  2017cites this paper
• The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes.

  2017cites this paper
• Pharmacological Treatment in Diabetes Mellitus Type 1 – Insulin and What Else?

  2017cites this paper
• Inhibidores del cotransportador de sodio y glucosa tipo 2 (SGLT2), el riñón como objetivo en el control glucémico de la diabetes mellitus tipo 2

  2017cites this paper
• Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line

  2017cites this paper
• The treatment of type 2 diabetes mellitus in patients with chronic kidney disease: What to expect from new oral hypoglycemic agents.

  2017cites this paper
• Neue Therapieansätze bei Typ-2-Diabetes und hohem kardiovaskulärem Risiko

  2016cites this paper
• Lipids and bariatric procedures Part 2 of 2: scientific statement from the American Society for Metabolic and Bariatric Surgery (ASMBS), the National Lipid Association (NLA), and Obesity Medicine Association (OMA).

  2016cites this paper
• The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies

  2016cites this paper
• The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin

  2016cites this paper
• What’s next after metformin? focus on sulphonylurea: add-on or combination therapy

  2015cites this paper
• Canagliflozin: a sodium glucose co‐transporter 2 inhibitor for the treatment of type 2 diabetes mellitus

  2015cites this paper
• Empaglifl ozin and metformin combination therapy in Type 2 diabetes mellitus

  2015cites this paper
• β-selective C-arylation of silyl protected 1,6-anhydroglucose with arylalanes: the synthesis of SGLT2 inhibitors.

  2015cites this paper
• Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus.

  2015cites this paper
• SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin

  2015cites this paper
• Organo-zinc Promoted Diastereoselective C-Arylation of 1,2-Anhydrosugars from Arylboronic Acids.

  2015cites this paper
• β-Selective C-Arylation of Diisobutylaluminum Hydride Modified 1,6-Anhydroglucose: Synthesis of Canagliflozin without Recourse to Conventional Protecting Groups.

  2015cites this paper
• Effect of the sodium glucose co‐transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus

  2014cites this paper
• The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors.

  2014influential citation
• Synthesis of empagliflozin, a novel and selective sodium-glucose co-transporter-2 inhibitor, labeled with carbon-14 and carbon-13.

  2014cites this paper
• Correction: Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes

  2014cites this paper
• A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor

  2014cites this paper
• Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, for the Management of Type 2 Diabetes

  2014cites this paper
• SGLT-2-Inhibition mit Canagliflozin: Eine neue Option in der Therapie des Typ-2-Diabetes

  2014cites this paper
• Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes

  2014cites this paper
• Sodium Glucose Co-Transporter 2 Inhibitors and Their Mechanism for Improving Glycemia in Patients with Type 2 Diabetes

  2014cites this paper
• Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus

  2013cites this paper
• Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus

  2013influential citation
• Nonclinical Toxicology Assessments Support the Chronic Safety of Dapagliflozin, a First-in-Class Sodium-Glucose Cotransporter 2 Inhibitor

  2013cites this paper
• Kidneys function in glucose homeostasis regulation and its therapeutic implications

  2013cites this paper
• Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: treating "sick fat" through improving fat function with antidiabetes therapies.

  2012cites this paper
• Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus

  2012cites this paper
• Assessment of the Drug Interaction Risk for Remogliflozin Etabonate, a Sodium-Dependent Glucose Cotransporter-2 Inhibitor: Evidence from In Vitro, Human Mass Balance, and Ketoconazole Interaction Studies

  2012cites this paper
• Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin

  2012cites this paper
• Assessment of the Drug Interaction Risk for Remogliflozin Etabonate, a Sodium-Dependent Glucose Co-Transporter-2 Inhibitor: Evidence from In Vitro, Human Mass Balance and Ketoconazole Interaction Studies.

  2012influential citation
• Long‐term treatment with empagliflozin, a novel, potent and selective SGLT‐2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats

  2012cites this paper
• Assessment of Remogliflozin Etabonate, a Sodium-Dependent Glucose Co-Transporter-2 Inhibitor, as a Perpetrator of Clinical Drug Interactions: A Study on Drug Transporters and Metabolic Enzymes

  2012cites this paper
• Functional characterisation of human SGLT‐5 as a novel kidney‐specific sodium‐dependent sugar transporter

  2012cites this paper
• SGLT2 inhibitors: molecular design and potential differences in effect.

  2011cites this paper
• New oral antidiabetic agents

  2011cites this paper
• Incretin therapy--present and future.

  2011influential citation
• Renal glucose reabsorption inhibitors to treat diabetes.

  2011cites this paper
• Synthesis and SAR of Benzisothiazole- and Indolizine-β-d-glucopyranoside Inhibitors of SGLT2.

  2010cites this paper
• The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats

  2010cites this paper
• THE FUTURE OF TYPE 2 DIABETES MANAGEMENT: PREVENTION, EARLY INTERVENTION, AND PIPELINE MEDICATIONS *

  2009cites this paper